5-MeO-MBT, also known as 5-methoxy-N-methyl-N-butyltryptamine, is a serotonin receptor modulator of the tryptamine and 5-methoxytryptamine families related to 5-MeO-DMT.
The drug was not included nor mentioned in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved) and its properties and effects in humans are unknown.
It shows affinity for the serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>2C</sub> receptors (K<sub>i</sub> = 10nM, 721nM, and 252nM, respectively). The drug is a partial agonist of the serotonin 5-HT<sub>2A</sub> receptor ( = 1,318nM; = 38âÂÂ47%). Its affinities for the serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>2C</sub> receptors were similar to those of 5-MeO-DMT, and it showed only 1.8-fold lower activational potency at the serotonin 5-HT<sub>2A</sub> receptor, but it had much lower efficacy in activating the receptor in comparison ( = 38âÂÂ47% and 98%, respectively).
The chemical synthesis of 5-MeO-MBT has been described. 5-MeO-MBT has several possible positional isomers, including 5-MeO-MiBT, 5-MeO-MsBT, and 5-MeO-MtBT.
5-MeO-MBT was first described in the scientific literature by Niels Jensen in 2004.